Ascendis Pharma (ASND) Misses Q4 EPS by 775c

Ascendis Pharma (NASDAQ: ASND) reported Q4 EPS of (EUR10.40), EUR7.75 worse than the analyst estimate of (EUR2.65). Revenue for the quarter came in at EUR51.17 million versus the consensus estimate of EUR19.55 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Sypris Solutions (SYPR) Reports Q2 Loss of $0.14
• QT Imaging reports 116% revenue jump in first half of 2026